Cover Image
市場調查報告書

黏多醣症II(MPS II,韓特氏症候群):開發中產品分析

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 251572
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
Back to Top
黏多醣症II(MPS II,韓特氏症候群):開發中產品分析 Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H2 2016
出版日期: 2016年12月21日 內容資訊: 英文 71 Pages
簡介

韓特氏症或稱黏多醣症II(MPS II),是僅有男性會發病,並會出現影響身體各處症狀的疾病。症狀有爪狀手、舌頭突出、唇、舌、鼻孔肥大等五官變異 、發育遲緩等。治療有骨髓移植,酵素治療及基因治療等。

本報告提供全球各國治療黏多醣症II(MPS II,韓特氏症候群)所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

黏多醣症II概要

治療藥的開發

  • 黏多醣症II開發中產品:概要
  • 黏多醣症II開發中產品:比較分析

各企業開發中的黏多醣症II治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 階段不明的產品

黏多醣症II治療藥:開發中的產品一覽(各企業)

黏多醣症II開發治療藥的企業

  • Alexion Pharmaceuticals, Inc.
  • AngioChem Inc.
  • ArmaGen Inc.
  • Bioasis Technologies Inc.
  • Green Cross Corporation
  • Inventiva
  • JCR Pharmaceuticals Co., Ltd.
  • Laboratorios Del Dr. Esteve S.A.
  • RegenxBio Inc.
  • Sangamo BioSciences, Inc.
  • Shire Plc

黏多醣症II:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

黏多醣症II治療藥:暫停的計劃

黏多醣症II治療藥:中止開發的產品

黏多醣症II相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8838IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H2 2016, provides an overview of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Metabolic Disorders) pipeline landscape.

Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a condition that affects many different parts of the body and occurs almost exclusively in males. Signs and symptoms include claw-like hands, protruding tongue, changing facial features, including thickening of the lips, tongue and nostrils and delayed development. Treatment includes bone marrow transplantation, enzyme therapy and gene therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 1, 8 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Overview
  • Therapeutics Development
  • Pipeline Products for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Overview
    • Pipeline Products for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Comparative Analysis
    • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Therapeutics under Development by Companies
    • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Therapeutics under Investigation by Universities/Institutes
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Products under Development by Companies
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Products under Investigation by Universities/Institutes
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Companies Involved in Therapeutics Development
    • Alexion Pharmaceuticals Inc
    • AngioChem Inc
    • ArmaGen Inc
    • Bioasis Technologies Inc
    • Green Cross Corp
    • Inventiva
    • JCR Pharmaceuticals Co Ltd
    • Laboratorios Del Dr Esteve SA
    • RegenxBio Inc
    • Sangamo BioSciences Inc
    • Shire Plc
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AGT-182 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DUOC-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EGT-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Iduronate 2 Sulfatase for Mucopolysaccharidosis II - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • idursulfase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • idursulfase beta - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JR-032 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JR-141 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MTf-I2S - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MTfp-I2S - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • odiparcil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pentosan polysulfate sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Enzymes for Pompe, Fabry and Hunter Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Iduronate 2-Sulfatase Replacement for Mucopolysaccharidosis II - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RGX-121 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-913 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Dormant Projects
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Discontinued Products
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 26, 2016: National Center for Child Health and Development Initiates Phase 1/2 Trial of Green Cross' idursulfase-beta ICV for the Treatment of Hunter Syndrome with Neurocognitive Decline
      • Sep 13, 2016: REGENXBIO Publishes Data from Ongoing Preclinical Studies of NAV Gene Therapy RGX-121
      • Jul 05, 2016: REGENXBIO Provides Update On Gene Therapy Development Program RGX-121
      • Jun 20, 2016: Sangamo BioSciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II
      • Apr 19, 2016: Preclinical Data from REGENXBIO's RGX-121 Gene Therapy Program to be Presented at the American Society of Gene & Cell Therapy 19th Annual Meeting
      • Feb 25, 2016: ESTEVE Provides Update On EGT-301 For Hunter Syndrome
      • Jul 31, 2015: biOasis Announces the Successful Delivery to the CNS of an Enzyme used to Treat Hunter Syndrome
      • Sep 18, 2014: biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation
      • Oct 02, 2013: Green Cross Exports Orphan Disease Drug Hunterase to Algeria
      • Apr 08, 2013: Green Cross Announces Publication Of Clinical Trial Paper On Hunter Syndrome Drug Hunterase In International Scientific Press
      • Feb 18, 2013: Green Cross Receives FDA Orphan Drug Designation For Hunterase For Treatment Of Hunter Syndrome
      • Jan 10, 2012: Green Cross Receives Korean Approval For Hunterase
      • Oct 12, 2011: Green Cross Files Application For Korean Approval Of Hunterase For Treatment Of Hunter Syndrome
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), H2 2016
  • Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Alexion Pharmaceuticals Inc, H2 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by AngioChem Inc, H2 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by ArmaGen Inc, H2 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Bioasis Technologies Inc, H2 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Green Cross Corp, H2 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Inventiva, H2 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by JCR Pharmaceuticals Co Ltd, H2 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Laboratorios Del Dr Esteve SA, H2 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by RegenxBio Inc, H2 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Sangamo BioSciences Inc, H2 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Shire Plc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Dormant Projects, H2 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), H2 2016
  • Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top